With $12M raised to date to support early development activities, ReBio is a development stage ophthalmics biotech seeking an additional $5M on a $25M pre-money valuation to reach Clinical Phase II for its two products based on SiSu®, their customisable, non-device, resorbable sustained release (SR) platform for the delivery of vision-preserving treatments with just 1 to 2 doses per year.
Current SR platforms have failed to deliver effective and long-acting treatments. SiSu® pre-clinical data has demonstrated greater safety, control, and a broader range of potential drug targets and indications than any sustained release platform under development.
ReBio’s lead program is RBLP, the first SR formulation of latanoprost, the current standard of care for the treatment of glaucoma, replacing daily eye drops with just 2 injections per year, and has already had positive feedback from the US FDA. ReBio’s second product is RBDX, an SR formulation of dexamethasone, the current standard of care for the prevention of glaucoma post-surgical inflammation, replacing 8 times daily eye drops for up to 3 months with a single injection given during the initial surgery.
In a market for chronic eye diseases worth $40B+ (+5.6% CARG/Year), ReBio was founded in 2015 in Helsinki, Finland and has a global presence (EU, UK, HK). Revenue for RBLP alone is projected to reach $450M+/year by 2032 with a conservative estimate of just 5% of the US market. ReBio’s team of 5 combines 100+ years of commercial, biotechnology, life science, and regulatory expertise.
We aim to close this round by 31 September 2022, with some minority investors already committed to join with $1M. $250k is the minimum investment ticket size.
Get in touch with Marco Torregrossa to find out more.